NCT04303988View on ClinicalTrials.gov

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 30, 2020

Primary Completion Date

December 30, 2024

Study Completion Date

May 30, 2025

Conditions
Breast Cancer
Interventions
DRUG

SHR-1316

IV

DRUG

Bevacizumab

IV

DRUG

Cisplatin/Carboplatin

IV

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04303988 - A Phase II Study of Triple-negative Breast Cancer Brain Metastases. | Biotech Hunter | Biotech Hunter